Arbutus Biopharma Corp ABUS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABUS is a good fit for your portfolio.
News
-
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
-
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
-
Arbutus to Participate in Two Upcoming Investor Conferences
-
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
-
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
-
Arbutus Biopharma Sues Pfizer, BioNTech Over Alleged Patent Infringement — Update
-
Arbutus Biopharma Sues Pfizer, BioNTech Over Alleged Patent Infringement
Trading Information
- Previous Close Price
- $2.75
- Day Range
- $2.68–2.75
- 52-Week Range
- $1.69–3.29
- Bid/Ask
- $2.71 / $2.84
- Market Cap
- $490.08 Mil
- Volume/Avg
- 323,341 / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 25.16
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 73
- Website
- http://www.arbutusbio.com
Comparables
Valuation
|
Metric
|
ABUS
|
AVIR
|
ENTA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.41 | 0.56 | 1.45 |
Price/Sales | 25.16 | — | 3.76 |
Price/Cash Flow | — | — | — |
Price/Earnings
ABUS
AVIR
ENTA
Financial Strength
|
Metric
|
ABUS
|
AVIR
|
ENTA
|
|---|---|---|---|
Quick Ratio | 5.68 | 17.86 | 6.04 |
Current Ratio | 5.87 | 18.24 | 6.25 |
Interest Coverage | −170.10 | — | — |
Quick Ratio
ABUS
AVIR
ENTA
Profitability
|
Metric
|
ABUS
|
AVIR
|
ENTA
|
|---|---|---|---|
Return on Assets (Normalized) | −36.64% | −15.46% | −27.96% |
Return on Equity (Normalized) | −49.55% | −16.16% | −47.34% |
Return on Invested Capital (Normalized) | −52.80% | −19.92% | −44.45% |
Return on Assets
ABUS
AVIR
ENTA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pknyfxpwr | Fmwj | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tbtsdxks | Kxxbjzp | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wvvltxlv | Hxytzl | $99.5 Bil | |
MRNA
| Moderna Inc | Wsgxtyr | Sszgb | $38.8 Bil | |
ARGX
| argenx SE ADR | Lcsstxjg | Jsz | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Sjwgfmjck | Gkpcp | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Yqvgbszm | Kmvny | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xflcgymq | Qslgfk | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fgywfzvt | Pdktytq | $12.5 Bil | |
INCY
| Incyte Corp | Lpjpsnbcn | Tfydhm | $11.6 Bil |